Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone206-325-6086
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
OptionableNot Optionable
Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions
What is Atossa Genetics' stock symbol?
Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."
When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?
Atossa Genetics shares reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.
How were Atossa Genetics' earnings last quarter?
Atossa Genetics Inc (NASDAQ:ATOS) posted its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.01. View Atossa Genetics' Earnings History.
When is Atossa Genetics' next earnings date?
What price target have analysts set for ATOS?
2 equities research analysts have issued 1 year price objectives for Atossa Genetics' stock. Their forecasts range from $5.00 to $10.00. On average, they expect Atossa Genetics' stock price to reach $7.50 in the next year. This suggests a possible upside of 458.7% from the stock's current price. View Analyst Price Targets for Atossa Genetics.
What is the consensus analysts' recommendation for Atossa Genetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atossa Genetics.
Has Atossa Genetics been receiving favorable news coverage?
News stories about ATOS stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Atossa Genetics earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.
Who are some of Atossa Genetics' key competitors?
Some companies that are related to Atossa Genetics include Lianluo Smart (LLIT), PAVmed (PAVM), DarioHealth (DRIO), Dynatronics (DYNT), Neovasc (NVCN), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP), Invivo Therapeutics (NVIV), Biostage (BSTG), Alliqua Biomedical (ALQA), Valeritas (VLRX), Presbia (LENS), Neurometrix (NURO), Avinger (AVGR) and Viatar CTC Solutions (VRTT).
Who are Atossa Genetics' key executives?
Atossa Genetics' management team includes the folowing people:
- Dr. Steven C. Quay, Chairman, CEO & Pres (Age 67)
- Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 54)
- Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
- Mr. Pieter Van Der Poel, VP of European Commercial Operations (Age 55)
- Dr. Jack Cuzick, Member of Scientific Advisory Board
Who are Atossa Genetics' major shareholders?
Atossa Genetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (1.24%). Company insiders that own Atossa Genetics stock include H Lawrence Remmel and Kyle Guse. View Institutional Ownership Trends for Atossa Genetics.
Which major investors are buying Atossa Genetics stock?
ATOS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Atossa Genetics stock in the last two years include H Lawrence Remmel and Kyle Guse. View Insider Buying and Selling for Atossa Genetics.
How do I buy shares of Atossa Genetics?
Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atossa Genetics' stock price today?
One share of ATOS stock can currently be purchased for approximately $1.3424.
How big of a company is Atossa Genetics?
Atossa Genetics has a market capitalization of $7.58 million. Atossa Genetics employs 7 workers across the globe.
What is Atossa Genetics' official website?
How can I contact Atossa Genetics?
Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]
MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
